Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

Rakesh Popat, Zoe Craig, Faith E Davies, David Cairns, Catherine Olivier, J Anthony Child, Gareth J. Morgan, Gordon Cook, Graham H Jackson

Blood (2021) 138 (Supplement 1): 4118.

https://doi.org/10.1182/blood-2021-149148

Published: 2021

Journal Articles

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK

Holly Cranmer, Tanja Podkonjak, Eugene Benson, Jonathon Dabora, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142338

Published: 2020

Journal Articles

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Amy Barber, PhD, John R Jones, MD, Harvey Che, Yann-Vai Le Bihan, Niels Weinhold, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Hannah Wang, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Faith E. Davies, Rajesh Chopra, MD, Gareth Morgan, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140024

Published: 2020

Journal Articles

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Tom Menzies, Faith E. Davies, Ritika Rana, Jennifer Pinney, Gordon Cook, MD, Walter Martin Gregory, PhD, Matthew W Jenner, John R Jones, MD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Gareth Morgan, MD PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, David Cairns, MSc, PhD, Mark T Drayson, MB ChB, PhD FRCPath

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-139238

Published: 2020

Journal Articles

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, MD, David Cairns, MSc, PhD, Tom Menzies, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Eileen M Boyle, MD MSc, Gareth Morgan, MD PhD, Gordon Cook, MB ChB, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Walter M Gregory, PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Brian Walker, PhD, Jennifer LJ Heaney, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Faith E. Davies

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-133516

Published: 2020

Journal Articles

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Charlotte A. Bradbury, Zoe Craig, Gordon Cook, Charlotte Pawlyn, David A. Cairns, Anna Hockaday, Andrea Paterson, Matthew W. Jenner, John R. Jones, Mark T. Drayson, Roger G. Owen, Martin F. Kaiser, Walter M. Gregory, Faith E. Davies, J. Anthony Child, Gareth J. Morgan, Graham H. Jackson

Blood (2020) 136 (9): 1091–1104.

https://doi.org/10.1182/blood.2020005125

Published: 2020

Includes: Supplemental data

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2018-99-118868

Published: 2018

Journal Articles

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood (2018) 132 (6): 587–597.

https://doi.org/10.1182/blood-2018-03-840132

Published: 2018

Includes: Supplemental data

Journal Articles

Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study

Charlotte A Bradbury, PhD MD FRCPath, FRCP, MSc, Matthew W Jenner, Alina Striha, MSc, Gordon Cook, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, John R Jones, MD, David Cairns, BSc, MSc, PhD, Anna Hockaday, Andrea Paterson, Mark T Drayson, MD PhD, Roger G Owen, MD, Martin F Kaiser, MD, Walter M Gregory, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Graham H Jackson, MDPhD

Blood (2017) 130 (Supplement 1): 553.

https://doi.org/10.1182/blood.V130.Suppl_1.553.553

Published: 2017

Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD

Blood (2016) 128 (22): 245.

https://doi.org/10.1182/blood.V128.22.245.245

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Journal Articles

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Blood (2016) 128 (22): 3271.

https://doi.org/10.1182/blood.V128.22.3271.3271

Published: 2016

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Sarah E Fordham, PhD, Helen J Blair, PhD, Claire J Elstob, PhD, Deepali Pal, PhD, Nicola Curtin, PhD, Paul Milne, PhD, Matthew Collin, MD PhD, Graham H Jackson, MD MBBS, Helen J Marr, MD PhD, Olaf Heidenreich, PhD, Ruth Plummer, John Pollard, PhD, Tobias F. Menne, MD PhD FRCPath, Gail L Jones, MD BMBS, James M Allan, DPhil

Blood (2016) 128 (22): 4031.

https://doi.org/10.1182/blood.V128.22.4031.4031

Published: 2016

Journal Articles

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Blood (2016) 128 (22): 4412.

https://doi.org/10.1182/blood.V128.22.4412.4412

Published: 2016

NARROW

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Thrombotic Events in Patients with Myeloma Treated with Immunomodulatory Drugs; Results of the Myeloma XI Study

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only